# US 2012/0252824 A1 · Drug Combinations and Uses in Treating a Coughing Condition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252824 A1
- Document ID: US20120252824A1
- Status: Published application
- Kind: A1
- Application number: 13/446,217
- Filed: 2012-04-13
- Published: 2012-10-04
- Earliest claimed: 2009-06-16
- Inventors: John Brew; Robin Mark Bannister
- Web page: https://patentgrep.com/patent/US20120252824A1

## CPC

- A61K 33/02: Ammonia; Compounds thereof
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K 31/09: having two or more such linkages
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/195: having an amino group
- A61K 31/401: Proline; Derivatives thereof, e.g. captopril
- A61K 31/4402: only substituted in position 2, e.g. pheniramine, bisacodyl
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 36/534: Mentha (mint)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/06: Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 1/10: Laxatives
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 11/14: Antitussive agents
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/20: Hypnotics; Sedatives
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present specification discloses compositions comprising a plurality of therapeutic compound having antitussive activity and methods and uses for treating a coughing condition with such compositions.

## Claims

### Claim at position 1

1-82. (canceled)

### Claim 83

A composition comprising a methylxanthine and a plurality of additional therapeutic compounds having antitusive activity.

### Claim 84 (depends on 83)

The composition according to claim 83, wherein the methylxanthine includes Aminophylline, Caffeine, IBMX, Paraxanthine, Pentoxifylline, Theobromine, Theophylline, Xanthine, or any combination thereof.

### Claim 85 (depends on 83)

The composition according to claim 83, wherein the plurality of therapeutic compounds having antitusive activity includes a non-opiate anti-tussive agent, an opiate anti-tussive agent, a decongestant, an expectorant, a mucolytic agent, an anti-histamine, a non-steroidal anti-inflammatory drug (NSAID), a neuropathic pain agent, a terpene, an ACE inhibitor, an angiotensin II receptor antagonist or any combination thereof.

### Claim 86 (depends on 83)

The composition according to claim 83, wherein the pharmaceutical composition reduces an unwanted side.

### Claim 87 (depends on 86)

The composition according to claim 86, wherein the unwanted side includes sedation, cognitive fogging, dizziness, drowsiness, postural hypertension, coordination problems, weakness, tremors, respiratory depression, psychotropic effects, sleep disturbances, unwanted waitfulness, CNS stimulation, weight gain, appetite change, change in sexual function, constipation, dry mouth, gut erosion, gastric ulcerations, renal inflammation, cardiovascular hypertension, cardiovascular stimulation, hyperchlimina, not going into public, chest pain, stress incontinence, or any combination thereof.

### Claim 87 (depends on 88)

The composition according to claim 88, wherein the antitussive activity reduces a symptom associated with a coughing condition by at least 10%.

### Claim 88 (depends on 83)

The composition according to claim 83, wherein the antitussive activity reduces a symptom associated with a coughing condition.

### Claim 88 (depends on 88)

The composition according to claim 88, wherein the symptom includes the frequency of a cough, the severity of a cough, the volume or noise level of a cough, hoarseness, sore throat, breathing difficulty, respiratory congestion, wheezing, respiratory constriction, respiratory inflammation, muscle spasms associated with a cough, phlegm production, fainting, insomnia, vomiting, subconjunctival hemorrhage (red eye), cough defecation, cough urination, abdominal hernia, pelvic hernia, costochondritis, or lower rib fracture.

### Claim 89 (depends on 83)

The composition according to claim 83, wherein the antitussive activity suppresses a vagal nerve function associated with a cough.

### Claim 90 (depends on 89)

The composition according to claim 89, wherein the antitussive activity suppresses a vagal nerve function associated with a cough by at least 10%.

### Claim 91 (depends on 83)

A method of treating a coughing condition in an individual, the method comprising the step of administering a composition according to claim 83, wherein administration reduces a symptom associated with the coughing condition.

### Claim 92 (depends on 91)

The method according to claim 91, wherein the coughing condition comprises an acute coughing condition.

### Claim 93 (depends on 91)

The method according to claim 91, wherein the coughing condition comprises a subacute coughing condition.

### Claim 94 (depends on 91)

The method according to claim 91, wherein the coughing condition comprises a chronic coughing condition.

### Claim 95 (depends on 91)

The method according to claim 91, wherein the coughing condition comprises a non-productive coughing condition.

### Claim 96 (depends on 91)

The method according to claim 91, wherein the coughing condition comprises a productive coughing condition.

### Claim 97 (depends on 91)

The method according to claim 91, wherein the coughing condition comprises a cough associated with a disease or disorder.

### Claim 98 (depends on 97)

The method according to claim 97, wherein the disease or disorder is an asthma, an atopic cough a bronchitis, a gastroesophageal reflux disease (GERD), an infection of the respiratory tract, an inflammation, a medication, a pollutant, a post-nasal drip, a smoking event, a vagal nerve irritation, a diseases of the external auditory canal, a lung disease, a lung tumor, a habit cough, a tic, a Tourette syndrome, a cardiovascular disease, or a post-infectious cough.

### Claim 99 (depends on 91)

The method according to claim 91, wherein administration of the pharmaceutical composition reduces an unwanted side.

### Claim 100 (depends on 99)

The method according to claim 99, wherein the unwanted side includes sedation, cognitive fogging, dizziness, drowsiness, postural hypertension, coordination problems, weakness, tremors, respiratory depression, psychotropic effects, sleep disturbances, unwanted waitfulness, CNS stimulation, weight gain, appetite change, change in sexual function, constipation, dry mouth, gut erosion, gastric ulcerations, renal inflammation, cardiovascular hypertension, cardiovascular stimulation, hyperchlimina, not going into public, chest pain, stress incontinence, or any combination thereof.

### Claim 101 (depends on 91)

The method according to claim 91, wherein the symptom includes coughing, hoarseness, sore throat, breathing difficulty, respiratory congestion, wheezing, respiratory constriction, respiratory inflammation, muscle spasms associated with a cough, phlegm production, fainting, insomnia, vomiting, subconjunctival hemorrhage (red eye), cough defecation, cough urination, abdominal hernia, pelvic hernia, costochondritis, lower rib fracture, or any combination thereof.
